Eaton Veterinary Pharmaceutical, Inc.

Eaton Veterinary Pharmaceutical, Inc. operates as Roadrunner Pharmacy, providing comprehensive veterinary products and services tailored to enhance animal health and wellness across veterinary practices of various sizes. Eaton Veterinary Pharmaceutical, Inc. , known as Roadrunner Pharmacy, specializes in veterinary pharmaceuticals and services.

Founded in 1999 and headquartered in Phoenix, US, the company has undergone strategic transformations, including its acquisition by Direct Vet Marketing in August 2017. The firm has completed 3 deals since its inception, with the most recent deal occurring in 2017. The company's founder's background is not specified in available information. Eaton Veterinary Pharmaceutical, Inc.

offers a wide range of veterinary products and services, including pharmaceuticals, nutritional supplements, grooming supplies, and veterinary equipment. These items are essential for veterinary professionals in diagnosing and treating various conditions in both companion animals and livestock. Notable offerings include Simparica Trio®, providing extensive parasite protection for dogs, and Bravecto® Chewables, effective in controlling flea and tick infestations. The company caters to a diverse clientele, including veterinary clinics and animal hospitals throughout North America.

The revenue model of Eaton Veterinary Pharmaceutical, Inc. encompasses direct sales to veterinary practices as well as partnerships in the veterinary industry. Key revenue sources include sales of pharmaceuticals and health products, supported by promotional strategies like bulk purchase incentives. The firm aims to enhance profitability for veterinary practices by offering value-added services that improve inventory management and streamline transaction processes.

Eaton Veterinary Pharmaceutical, Inc. plans to expand its product lineup with upcoming releases aimed at improving veterinary care. The company is also looking to enter new geographic markets, with specific plans to target regions in North America by the end of 2023. Recent funding from the acquisition by Direct Vet Marketing in August 2017 will be strategically utilized to support the development of these initiatives.